NEW YORK, Jan. 29, 2019 /PRNewswire/ -- At a gathering of
institutional investors this morning, Atomic Capital and Agenus Inc
(NASDAQ: AGEN), announced the launch of a groundbreaking
digital securities offering enabling the direct participation of
accredited investors in Agenus' lead immuno-oncology asset. The
proceeds from the digital securities offering, the first conducted
by a publicly-traded company, will go to fund product development
through FDA approval and commercialization, of the asset, with
returns to investors backed by future product sales.
"Atomic Capital is deeply committed to leveraging the
transformative capabilities of Distributed Ledger Technology in the
pursuit of our mission to make capital smarter." said
Alexander S. Blum, CEO of Atomic
Capital. "We are privileged to be working alongside Dr. Armen and
his remarkable team, bringing precision capital to precision
medicine."
Digital securities built on a distributed ledger use smart
contracts to enforce compliance and investor protection while also
providing access to secondary liquidity via 24/7 global
markets.
"We are excited to be working with Atomic Capital, an innovator
in emerging blockchain-based digital securities, in the launch of
the first of its kind Biotech Electronic Security Token,"
said Garo Armen, PhD Chairman and
CEO of Agenus. "We believe this unique instrument will pave
the way for allowing targeted investment by any qualified investor
in the development of therapeutic drugs and has the potential to
transform how drug development is financed."
Atomic Capital also announced this morning the launch of the
digital securities offerings of two additional clients on their
platform; a US-licensed, digital bank, and a blockchain-enabled
digital AdTech company.
About Atomic Capital
Atomic Capital is a technology
and financial group with a digital investment banking platform
leveraging smart contracts and to automate the compliant offering,
sale, and issuance of digital securities to investors. Atomic
Capital delivers the core technology, global relationships, and
industry experience to bring growth capital to exceptional
investments across the infrastructure, software, and life sciences
sectors. Atomic Capital is headquartered in New York City. For more information, visit
www.atomiccapital.io and follow on Twitter at @Atomic_Capital.
About Agenus Inc
Agenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics, proprietary
cancer vaccine platforms, and adoptive cell therapies (through its
AgenTus Therapeutics subsidiary). The Company is equipped with a
suite of antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support early phase
clinical programs. Agenus is headquartered in Lexington, MA. For more information, please
visit www.agenusbio.com and on twitter @agenus_bio.
Atomic Capital and its affiliates are licensed with LoHi
Securities, A Registered Broker-Dealer, Member FINRA/SIPC,
1888 Sherman Street, Suite 770 Denver, CO 80203 USA. 720-465-5305. LoHi
Securities and Atomic Capital, Inc. are not affiliated
entities.
View original
content:http://www.prnewswire.com/news-releases/atomic-capital-kicks-off-investor-forum-announcing-digital-offering-for-nasdaq-traded-biotech-group-agenus-inc-300785633.html
SOURCE Atomic Capital